JPRN-jRCTb030210237进行中（未招募）1 期
G-CSF-mobilized peripheral blood-derived autologous CD34+ cell transplantation for patients with chronic kidney disease
Ohtake Takayasu0 个研究点目标入组 4 人开始时间: 2021年8月12日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 4
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 80age old（—）
- 性别
- All
入选标准
- •1) Patients with chronic kidney disease.
- •2) Patients who are undergoing medical and diet treatment for chronic kidney disease.
- •3) Patients with CKD stage G3b~G4 and progressive kidney dysfunction under standard medical and diet treatment.
- •4) Patients aged 20~80 years old.
- •5) Patients with written informed consent.
排除标准
- •1) Patients without data of kidney function within preceding 12 months.
- •2) Patients who are admitting in hospital.
- •3) Dialysis patients.
- •4) Past history of renal transplantation (both recipient and donor).
- •5) Single kidney or single functioning kidney.
- •6) Patients who underwent contrast media-enhanced imaging test or catheter angiography/intervention within recent 1 month.
- •7) Patients who underwent surgical treatment within recent 1 month.
- •8) Severely damaged cardiac function (EF<25%).
- •9) Allergic reaction to G-CSF, apheresis.
- •10) Allergic reaction to mouse anti CD34 antibody in reagents.
- •11) Malignancy or past history within past 5 years.
- •12) Diabetic proliferating retinopathy.
- •13) Within 3 months from angina pectoris, myocardial infarction, or stroke.
- •14) Leukemia, myeloproliferative disorder, myelodysplastic syndrome, sickle cell anemia.
- •15) Liver cirrhosis.
- •16) Interstitial pneumonia.
- •17) Cerebral arterial aneurysm which need treatment.
- •18) White blood cell count under 3,000/micro L or over 10,000/micro L.
- •19) Platelet count under 50,000/micro L.
- •20) Hemoglobin under 8g/dL.
- •21) AST (GOT) or ALT (GPT) 100 IU/L or over.
- •22) Albumin under 2g/dL.
- •23) Splenomegaly 15 cm or Larger in its longest diameter on CT imaging.
- •24) Pregnant.
- •25) Patient of HBV, HCV, HIV or HTLV1.
- •26) Participant of other clinical study.
- •27) Patients who are judged not to be appropriate to participate in this study.
研究者
相似试验
进行中（未招募）
3 期
A Phase III randomized, double-blinded, placebo-controlled trial to investigate the impact of intra-coronary transfusion of G-CSF mobilized autologous circulating hematopoietic stem/progenitor cells (CPC) therapy in patients with diffuse coronary artery disease who are not candidates for coronary artery interventioDiffuse Coronary Artery Disease (CAD) and non candidates for coronary artery interventionCirculatory SystemISRCTN14054375Chang Gung Memorial Hospital, Chang Gung Medical Foundation96
已完成
不适用
Transplantation of autologous and G-CSF mobilized mononuclear cells in patients with critical limb ischemia (CLI)JPRN-UMIN000005227Regenerative Medicine Unit, Division of Vascular Regeneration Therapy, Institute of Biomedical Research and Innovation (IBRI)5
终止
不适用
Application of autologous peripheral blood-derived stem cell/progenitor cell (CD34+) + stem cells and hyperbaric oxygen therapy for patients with severe limb ischemiaISRCTN80181257Ministry of Science and Technology (Taiwan)40
招募中
3 期
se of stem cells which have capacity to grow to liver cells in patients of cirrhosis of liver who have jaundice, ascites( water in abdomen)CTRI/2017/11/010429Asian Healthcare Foundation
招募中
1 期
CD34+ cell transplantation for patients with acute renal failure.JPRN-jRCTb030190231OHTAKE Takayasu9